NRX Pharmaceuticals (NRXP) Stock Forecast & Price Target

NRX Pharmaceuticals is supported by a credible, catalyst-rich pipeline anchored by NRX-100 and NRX-101, both built on known molecules with substantial existing clinical evidence for suicidality and bipolar depression, which lowers scientific risk relative to novel drug development. The company’s outlook is strengthened by explicit FDA submission activity, potential approvals in 2026/27, a large unmet need with no approved medicine for bipolar depression with suicidal ideation, and a sizable addressable market supported by NIH prevalence data and long-lived suicide risk in bipolar patients. Financially, the stock also benefits from a more durable commercialization story through KETAFREE, HOPE Therapeutics, and non-dilutive funding opportunities, while the reported $26.7 million cash position and over $11.5 million in anticipated DARPA-related funding help support execution.

NRX Pharmaceuticals is facing fundamental pressure from a weak 2Q 2026 showing, with revenue of $1.1 million versus $3.0 million to $16.6 million expected, a $16.5 million net loss, and $7.6 million of operating expenses that exceeded estimates. Its balance sheet remains strained, with about $26.7 million in cash and securities, a $4.7 million working capital deficit, and substantial-doubt going-concern language, while the expected $50 million equity raise did not occur and only $22.3 million from the June 4 offering plus $8.4 million of ATM issuance supported liquidity. Commercial execution also looks soft: HOPE revenue was flat sequentially at $1.1 million, the clinic rollout slipped to six Florida locations, and NRX-100 and NRX-101 launches were pushed into 2027 amid regulatory and development uncertainty.